Novo Nordisk expanded a deal with Valo Health to discover and develop treatments for obesity, type 2 diabetes and cardiovascular disease using human data and artificial intelligence. The deal extends ...

Drugs for metabolic diseases, vaccines and cancer therapies feature among new product launches this year that could top $1 ...

At least four analysts weighed in on the prospects for Europe’s second-largest company, Novo Nordisk, after the Danish ...

SOUTH SAN FRANCISCO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company”) announced today that its SomaScan™ Platform played a pivotal role in a study ...

Scope of collaboration originally signed in 2023 will significantly expand to enable the discovery and development of up to ...

The investment continues a Novo dealmaking spree to cement its leadership status in the cardiometabolic space, with ...

Novo Nordisk is doubling down on its computational biotech partner Valo Health, expanding their collaboration from 11 ...

The deal expands a deal to discover and develop treatments for obesity, type 2 diabetes and cardiovascular disease using ...

Minutes from the meeting will be published at 2 p.m. Eastern on Wednesday. The Federal Open Market Committee-the Fed's policymaking committee-last month voted to lower the federal-funds rate target ...

Here are some of the drugs that are predicted to become blockbusters in the next few years, according to Clarivate's latest ...

Novo Nordisk shares fell 30% in the fourth quarter on disappointing clinical trial data, concerns about its experimental ...

Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at ...